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Introduction
Age-related macular degeneration (AMD) is the leading cause of adult blindness in
industrialized countries, with a reported 1.47% prevalence and 1.75 million people affected
in the United States alone.1, 2 Both “wet” AMD, otherwise known as choroidal
neovascularization (CNV), and geographic atrophy (GA), the advanced “dry” form of AMD,
are considered advanced AMD. While anti-vascular endothelial growth factor therapy is
currently available to treat CNV, there are no proven forms of therapy for GA. Initially,
antioxidants and vitamins were suggested as a preventative therapy for those with signs of
“dry” AMD; however, later analysis by the Age-Related Eye Disease Study Research Group
demonstrated that this therapy has no real effect on GA progression.3 Therefore, it is
important to characterize “dry” AMD to elucidate its natural history and facilitate
advancements in treatment and outcomes.
Drusen, concentrated deposits of extracellular material found around the macula, are an
established marker for AMD. A different lesion type has been characterized and associated
with AMD. Mimoun et al. first described “les pseudodrusen bleus” in 1990, referring to
indistinct, interlacing yellowish lesions in the outer macula which are enhanced by blue
light.4 These were considered a type of drusen and were included in the Wisconsin Age-
Related Maculopathy Grading System as a separate entity called “reticular drusen,” based on
their characteristic appearance.5 However, initial histopathological analysis suggested that
these lesions are associated with a loss of choroidal layers of small vessels and increased
spacing between large choroidal veins not typical of AMD-associated drusen.6
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Reticular drusen, otherwise referred to as “reticular pseudodrusen,” are difficult to visualize
using color fundus photography; therefore, since the development of scanning laser
ophthalmoscope (SLO) imaging, including autofluorescence (AF) scans, near-infrared
reflectance (NIR) scans, and indocyanine green angiography, these lesions have been more
clearly characterized.7, 8 Notable spatial correspondence of individual lesions using different
imaging modalities was observed; from this observation, it was concluded that perhaps a
single disease entity is responsible.9 The term “reticular macular disease” was defined as
reticular pseudodrusen in color or red-free photography and/or a reticular pattern on SLO
imaging.9 Spectral domain optical coherence tomography (SD-OCT) scans further extended
the phenotypic characterization and, with histology, suggested anatomic correlation with
lesions in the subretinal space, known as “subretinal drusenoid deposits.”10-13 The etiology
of these lesions and the etiology of reticular pseudodrusen remain unclear. Other
histopathologic and blood flow studies of AMD describe degenerative changes in the
choriocapillaris and choroidal circulation insufficiency,14-17 and multimodal imaging of
patients with reticular lesions has suggested an alteration in choriocapillaris blood
flow.9, 18, 19
There may be genetic risk factors for the reticular pseudodrusen subtype of AMD. Two
major AMD risk alleles have been identified through genome-wide scanning and the
candidate gene approach.20-23 In a retrospective study, one of the two major AMD risk
alleles, complement factor H (CFH, rs1061170) 402H, was less associated with reticular
pseudodrusen than with the absence of reticular pseudodrusen (39.6% frequency in AMD
with reticular pseudodrusen vs. 58.6% in AMD without reticular pseudodrusen, P = 0.003).
The other major risk allele, age-related maculopathy susceptibility 2 (ARMS2, rs10490924)
69S, was associated with an enhanced risk of reticular pseudodrusen (44.0% frequency in
AMD with reticular pseudodrusen vs. 31.3% in AMD without reticular pseudodrusen, P =
0.045).24 In a larger study, no significant difference was found in the frequency of either risk
allele between eyes with AMD and reticular pseudodrusen and eyes with AMD and no
reticular pseudodrusen.25
While patients with reticular pseudodrusen make up only about 7-8% of patients with AMD,
as many as 32% of patients with CNV and 21% of patients with GA were found to have
reticular pseudodrusen on color fundus photography.26-28 In another study, reticular
pseudodrusen were found in more than 60% of patients with AMD on AF imaging, implying
that the prevalence of reticular pseudodrusen may be higher than previously recognized,29
and more recently, reticular pseudodrusen were found in over 90% of patients with GA.30
Interestingly, reticular pseudodrusen have been associated not only with both forms of late
AMD, particularly with conversion to CNV, but also with female gender, systemic disease,
and increased mortality.28
The etiology of reticular pseudodrusen is unclear. Recent discoveries suggest that this AMD
phenotype is complex and multifactorial, with possible genetic, environmental, and systemic
factors. We hypothesize that this is indeed the case, as previous epidemiologic studies have
suggested that reticular pseudodrusen are associated with cardiovascular risk factors and the
ARMS2 risk allele. This study aimed to investigate genetic, environmental, and systemic risk
factors in prospectively identified subjects with AMD and the phenotypes of (a) reticular
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pseudodrusen without large soft drusen and (b) large soft drusen without reticular
pseudodrusen.
Methods
This prospective cross-sectional study was carried out with approval from the Institutional
Review Board of New York University School of Medicine and in accordance with the
Health Insurance Portability and Accountability Act of 1996. Informed consent, obtained
from all study participants, included consent for participation in the study and permission to
review relevant medical records. Between July 2012 and February 2013, study participants
were recruited from two clinician's practices (KBF and RTS) and identified using clinical
examination, SD-OCT imaging, and SLO imaging with characteristics and methods as
described previously.9 Briefly, NIR images were obtained using a confocal SLO (Spectralis,
Heidelberg Engineering, Inc., Vista, CA). Two independent graders (SB and MM) detected
reticular pseudodrusen on IR imaging as groups of hyporeflectant lesions against a mildly
hyperreflectant background, in well-defined and regular patterns, and confirmed reticular
pseudodrusen by the presence of subretinal drusenoid deposits on SD-OCT imaging
obtained with the same instrument (Figure 1). Large (≥125 μm) soft drusen were identified
on color photographs by their characteristic yellow, indistinct appearance and confirmed by
the presence of mounds of deposits under the retinal pigment epithelium on SD-OCT
imaging (Figure 2). Any discrepancies were resolved by a senior grader (KBF or RTS).
Based on these findings, patients were classified into two study groups: (a) subjects with an
AMD phenotype of reticular pseudodrusen without large soft drusen and (b) subjects with an
AMD phenotype of large soft drusen without reticular pseudodrusen.
Accordingly, inclusion criteria were AMD and a phenotype of reticular pseudodrusen
without large soft drusen or AMD and a phenotype of large soft drusen without reticular
pseudodrusen. Exclusion criteria were media opacity that resulted in poor image quality,
photographic artifacts, or history of retinal vascular occlusion, retinal detachment, vitreo-
retinal or glaucoma surgery, retinal pigment epithelium tear, macular hole, central serous
chorioretinopathy, or high myopia (spherical equivalent greater than -6 diopters).
All patients completed an extensive questionnaire that collected demographic information
(age, race, and gender), personal and family history of AMD, smoking history, and history
of cardiovascular risk factors, including hypertension, diabetes, and hyperlipidemia, as well
as the use of medications being used to control these conditions. Elicited personal history of
AMD included the age at diagnosis. A patient was defined as having a family history of
AMD if he or she had any genetically related family member with AMD. Smoking history
included ascertaining if the patient had ever smoked cigarettes for a total duration of 6
months or more. Hypertension was defined as having been previously diagnosed with
elevated arterial blood pressure, which is being controlled by at least one hypertensive
medication. Hyperlipidemia was defined as having been previously diagnosed with elevated
blood lipid levels, which are being controlled by medication. Diabetes mellitus was defined
as having been previously diagnosed with elevated blood glucose, which is being controlled
by diet or medication.
Boddu et al. Page 3
Am J Ophthalmol. Author manuscript; available in PMC 2015 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Definitive CFH and ARMS2 genotyping was performed on all patients as follows: DNA was
screened for haplotype-tagging single-nucleotide polymorphisms in CFH (Y402H,
rs1061170) and ARMS2 (A69S, rs10490924). Genotyping was performed using polymerase
chain reaction-restriction fragment length polymorphism analysis using a master mix
(Applied Biosystems, Life Technologies, Norwalk, CT). The thermal cycling conditions
consisted of an initial hold at 95° C for 10 minutes, followed by 40 cycles of a 15-second
92° C denaturation step and a 1-minute 60° C annealing and extension step. Results were
acquired using Applied Biosystems ViiA 7 RUO Software (Life Technologies, Norwalk,
CT).
Allele frequencies were compared between the two study groups. We used the
nonparametric Kruskal-Wallis test to evaluate differences of quantitative variables between
the two groups. For categorical variables, we report odds ratios (ORs) and 95% confidence
intervals (CIs), with P-values calculated from the chi-squared test or Fisher's exact test. Age
and age at AMD onset were analyzed both as continuous variables and as categorical
variables, derived by dividing the overall distribution into tertiles. For ordinal variables, we
used Mantel's test for trend to statistically test for evidence of increasing risk with increasing
values.31 We performed multivariable analysis using exact logistic regression as
implemented in PROC LOGISTIC (SAS 9.3, 2002-2010, SAS Institute, Inc., Cary, NC).
Results
Thirty patients with a phenotype of reticular pseudodrusen and no evidence of large soft
drusen and 43 patients with a phenotype of large soft drusen and no evidence of reticular
pseudodrusen were classified, with an inter-observer grading concordance of 90%, and
enrolled in the study. The median age of patients included in the analysis was 87 years in the
reticular pseudodrusen group and 81 years in the soft drusen group (P = 0.04). Patients with
reticular pseudodrusen also had a significantly later age of AMD onset than patients with
soft drusen (83 years vs. 70 years, respectively, P = 0.0005). The final analysis set
comprised 46/73 (60.9%) women, with a significantly larger proportion of females in the
reticular pseudodrusen group than in the soft drusen group (25/30 (83.3%) vs. 21/43
(48.8%), respectively, P = 0.003). All patients with soft drusen (43/43, 100%) and most
patients with reticular pseudodrusen (29/30, 96.7%) were of European ancestry; 10/30
patients (33.3%) in the reticular pseudodrusen group and 9/43 patients (20.9%) in the soft
drusen group reported an immediate family member with AMD (P = 0.3). The distribution
of the ARMS2 risk allele did not significantly differ (P = 0.4) between the reticular
pseudodrusen (homozygous = 20.0%; heterozygous = 56.7%) and the large soft drusen
(homozygous = 19.0%; heterozygous = 42.9%) phenotypes. Similarly, the distribution of the
CHF risk allele did not significantly differ (P = 0.7) between the reticular pseudodrusen
(homozygous = 26.7%; heterozygous = 56.7%) and the large soft drusen (homozygous =
21.4%; heterozygous = 66.7%) phenotypes (See Table 1).
In Table 2, we show univariable analyses of risk factors for reticular pseudodrusen,
presenting the total sample of patients with AMD as having different values for (or
presence/absence of) each factor. For each risk factor, we show the frequency and
percentage of patients with reticular pseudodrusen, as well as ORs and 95% CIs for reticular
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pseudodrusen among those with a particular value of the risk factor compared to the
reference group of those without the risk factor. ORs for reticular pseudodrusen associated
with the ARMS2 and CFH risk alleles were not significantly different from the null value of
1.0. ORs for reticular pseudodrusen were significantly increased among older patients and
patients with later ages of AMD onset; the test for trend was significant in both cases.
There was a suggestion of an increased risk of reticular pseudodrusen with a history of
hypertension (OR = 2.6, 95% CI = 0.92 – 7.3, P = 0.08). A lifetime history of smoking for 6
months or longer was associated with a non-significantly elevated OR for reticular
pseudodrusen (OR = 1.4, 95% CI = 0.53 – 3.6, P = 0.6). A history of diabetes mellitus was
associated with a non-significantly reduced, or protective, OR for reticular pseudodrusen
(OR = 0.21, 95% CI = 0.02 – 1.9, P = 0.2).
Exact multiple logistic regression analysis found statistically significant and independent
risks for reticular pseudodrusen associated with female gender and age at AMD onset
(Table 3). Age, treated either as a three-level categorical variable or as a quantitative
variable, did not enter the multivariable model following entry of age at AMD onset and
gender.
Discussion
A previous retrospective study found an association between reticular pseudodrusen and the
ARMS2 risk allele, but not the CFH risk allele, among its two groups of patients: Group 1
comprised patients with AMD and reticular pseudodrusen (n = 67), and Group 2 comprised
patients with AMD and no reticular pseudodrusen (n = 64). The frequencies of the ARMS2
69S risk allele were 44.0% in Group 1 and 31.3% in Group 2 (OR = 1.73, P = 0.045). The
frequencies of the CFH 402H risk allele were 39.6% in Group 1 and 58.6% in Group 2 (OR
= 0.46, P = 0.003).24 A recent larger study found no significant association between reticular
pseudodrusen and either risk allele among its three groups of patients: Group 1 comprised
patients with AMD and reticular pseudodrusen (n = 105), Group 2 comprised patients with
AMD and no reticular pseudodrusen (n = 414), and Group 3 comprised controls with no
AMD and no reticular pseudodrusen (n = 430). The ORs for individuals homozygous for the
CFH risk allele were 4.0 (P < 0.0004) for Group 1 and 4.3 (P < 0.0004) for Group 2,
compared with Group 3. The ORs for individuals homozygous for the ARMS2 risk allele for
Groups 1 and 2 compared with Group 3 were 16.3 (P < 0.0004) and 11.9 (P < 0.0004),
respectively.25
To our knowledge, the association between reticular pseudodrusen and the ARMS2 and CFH
risk alleles has not been looked at prospectively until now. In addition, patients with AMD
and reticular pseudodrusen in the previous studies discussed above are not truly
representative of the reticular pseudodrusen phenotype as these patients may have had soft
drusen in addition to reticular pseudodrusen. In contrast, our study examined the genotypes
of carefully selected patients with AMD and reticular pseudodrusen but without any
evidence of soft drusen. In our study, there does not appear to be a significant association
between either of the two major risk alleles and reticular pseudodrusen.
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The mechanism of ARMS2 is still unknown. There is an association of ARMS2 with elevated
C-reactive protein,32 which may be relevant in the present context because C-reactive
protein is associated with both AMD and coronary artery disease. Prior studies have
suggested that reticular pseudodrusen are associated with systemic cardiovascular disease,
such as hypertension and angina, with an increased mortality rate in this population separate
from comorbidities.9, 24, 28 Our study suggested an elevated risk of reticular pseudodrusen
among patients with AMD with a history of hypertension. Hypertension did not, however,
enter our multiple logistic regression model after entry of gender and age at AMD onset. If
hypertension were a risk factor for reticular pseudodrusen, this would be consistent with a
disease process arising from vascular insufficiency.
Disturbances in the ocular circulation in AMD have been reported,33-39 and several
histopathological and blood flow studies of AMD have described degenerative changes in
the choriocapillaris and choroidal circulation insufficiency,14-17,40-43 supporting the role of
hemodynamic abnormalities, such as systemic hypertension, in AMD. In fact, Metelitsina et
al. reported that choroidal blood flow is approximately 16.7% lower in patients with AMD
with systemic hypertension than in patients with AMD without systemic hypertension.44
Sohrab et al. provided results suggesting that the arrangement and pattern of reticular
pseudodrusen are related closely to the choroidal stroma and the choroidal vasculature.45
Arnold et al. related the presence of reticular drusen to abnormalities in the inner choroid.6
In addition to possible vascular substrates for reticular pseudodrusen, the phenotypic
association with subretinal drusenoid deposits is also under investigation. An elegant and
recent two-lesion two-compartment model suggests that subretinal drusenoid deposits are a
sign of retinal pigment epithelium lipid recycling pathways resulting in a lipid and protein
spill into the subretinal space, with ensuing photoreceptor damage and ultimately geographic
atrophy.46 Querques et al. have suggested a unifying theory in which derangement of the
retinal pigment epithelium because of underlying choroidal atrophy and fibrosis may lead to
the accumulation of photoreceptor outer segments above the retinal pigment epithelium,
creating subretinal deposits.18
Our finding that later age of AMD onset is an independently significant risk factor for the
reticular pseudodrusen phenotype of AMD, in the setting of growing data supporting the
vascular insufficiency hypothesis of reticular pseudodrusen etiology, raises important
questions and warrants further study. Megnien et al., in a study published in Hypertension,
found that high blood pressure, and, in particular, the duration of exposure to high blood
pressure, promotes the presence and overall extent of coronary calcium, a potential predictor
of sudden coronary death.47 As evidenced previously in the ophthalmology literature,
reticular pseudodrusen have been linked to systemic diseases, such as hypertension and
angina, as well as increased mortality independent of comorbidities.9, 24, 28 It would be of
interest to study the role, if any, that the duration of exposure to high blood pressure has in
promoting choroidal insufficiency, choroidal atrophy, and choroidal fibrosis and in the
eventual manifestation of reticular pseudodrusen,18 a potential predictor of geographic
atrophy.48 It would also be of interest to study whether the later age of AMD onset in
patients with the reticular pseudodrusen phenotype is related to these same factors.
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Another interesting observation is the overwhelming proportion of females presenting with
the reticular pseudodrusen phenotype of AMD. We found a strong association of risk for
reticular pseudodrusen with female gender that was not affected by adjustment for age at
AMD onset or age. This finding has been reported elsewhere, but the reason for this
discrepancy between the genders has not been established.28 Given the growing evidence
linking cardiovascular disease and reticular pseudodrusen, it is possible that males are
underrepresented in this older population because of earlier death from cardiovascular
disease, which is in turn due to the lack of the cardio-protective effect of estrogen.49
There has also been recent interest in CFH haplotype analysis. Certain haplotypes may in
fact be protective against AMD, and it would be of interest to investigate whether any
haplotypes are associated with reticular pseudodrusen.50
Several potential weaknesses of the present study dictate the need for further research on
reticular pseudodrusen. The case-case design of the study provided estimates of ORs for
reticular pseudodrusen associated with various risk factors using a comparison group of
AMD without reticular pseudodrusen. Both the group of interest, i.e., those with reticular
pseudodrusen, and the referent group were patients with AMD. This would have increased
the frequency of both risk alleles in both groups. Hence, the study was designed to look for a
differential expression of the risk alleles in AMD depending on whether the underlying early
phenotype was reticular pseudodrusen or soft drusen. ORs for reticular pseudodrusen from
our study thus could be quite different from those obtained from a study whose comparison
group was healthy individuals without AMD, i.e., a case-control study. Another weakness of
the study was the small sample size, resulting in poor statistical power. The small numbers
of subjects could explain why some risk factors failed to be statistically significant in
multiple logistic regression analyses that included age at AMD onset and gender.
Recruitment of patients from tertiary referral medical practices may have biased the results
of our study. If, for example, primary care providers were more inclined to refer difficult-to-
treat AMD cases or AMD cases among the elderly to these practices, then our findings may
not reflect what would be found in an unbiased, population-based study.
Finally, the cross-sectional design of the study made it susceptible to prevalence-incidence
bias.51 Specifically, our study of prevalent cases of reticular pseudodrusen diagnosed in an
ophthalmologic practice may have missed information that would have been obtained in an
incidence study designed to capture information from patients who died soon after
development of reticular pseudodrusen. If, for example, reticular pseudodrusen are
associated with late-stage cardiovascular disease, then higher mortality from cardiovascular
disease at younger ages among men compared to women might explain the significantly
elevated OR for female gender in the present study. In other words, our study may have
provided ORs associated with survival to an age advanced enough to develop reticular
pseudodrusen in the context of AMD, rather than ORs for reticular pseudodrusen itself.
Prospective cohort studies of healthy individuals without AMD who are enrolled and then
monitored regularly for incident disease would avoid prevalence-incidence bias and thus
would have the best chance of elucidating our novel finding of the increased risk of reticular
pseudodrusen with later age of AMD onset.
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In summary, reticular pseudodrusen were significantly associated with increased age, later
age of AMD onset, and female gender. Our data also suggests an elevated risk of reticular
pseudodrusen among patients with hypertension, consistent with a disease process arising
from vascular insufficiency. The increased age and high proportion of women among
patients with reticular pseudodrusen clearly merits further investigation, perhaps by studying
a middle-aged cohort of men with cardiovascular disease for signs of reticular pseudodrusen,
as this population may be underrepresented at later ages. Further investigation of all these
factors is warranted because better understanding of the mechanism of reticular
pseudodrusen can potentially lead to a better understanding of the pathophysiology of AMD
and novel therapies for dry AMD.
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Figure 1.
Retinal fundus photographs of the right eye of an 89-year-old female with the reticular
pseudodrusen phenotype of age-related macular degeneration. The color photograph (top
left) demonstrates the classic presentation of reticular pseudodrusen, identified as yellow or
light interlacing networks. Also pictured are the corresponding near-infrared scanning laser
ophthalmoscope image of the same eye (top right), showing reticular pseudodrusen as
groups of hyporeflectant lesions against a mildly hyperreflectant background in a well-
defined pattern, and the optical coherence tomography scan (bottom) of the same eye,
showing reticular pseudodrusen as subretinal drusenoid deposits.
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Figure 2.
Retinal fundus photographs of the right eye of an 85-year-old male with the large soft drusen
phenotype of age-related macular degeneration. The color photograph (top left)
demonstrates the classic presentation of large soft drusen characterized by a yellow,
indistinct appearance. Also pictured are the corresponding near-infrared scanning laser
ophthalmoscope image (top right) of the same eye, showing large soft drusen as
hyperreflectant lesions, and the optical coherence tomography scan (bottom) of the same
eye, showing large soft drusen as mounds of deposits under the retinal pigment epithelium.
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Table 1
Description of subjects with the age-related macular degeneration phenotypes of (a) reticular pseudodrusen
without large soft drusen and (b) large soft drusen without reticular pseudodrusen.
AMDa with RPDb and without large
soft drusen, n (%)
AMD with large soft drusen and
without RPD, n (%)
P-value
Gender 0.003c
Male 5 (16.7) 22 (51.2)
Female 25 (83.3) 21 (48.8)
Race 0.4c
Non-Hispanic Caucasian 29 (96.7) 43 (100.0)
Hispanic 1 (3.4) 0 (0.0)
Age (years), median (q1-q3) 87 (81-89) 81 (74-88) 0.04d
Categorical age (years) 0.02e
≤ 80 6 (20.0) 19 (44.2)
81-86 7 (23.3) 13 (30.2)
≥ 87 17 (56.7) 11 (25.6)
Age at AMD onset (years), median (q1-q3) 83 (77-86) 70 (66-78) 0.0005d
Categorical age at AMD onset (years) 0.0006e
≤ 70 3 (10.0) 22 (51.2)
71-82 12 (40.0) 12 (27.9)
≥ 83 15 (50.0) 9 (20.9)
Years since AMD diagnosis, median (q1-q3) 3 (2-6) 7 (4-11) 0.002d
Family member with AMD 10 (33.3) 9 (20.9) 0.3c
Hypertension 0.08c
No 7 (23.3) 19(44.2)
Yes 23 (76.7) 24(55.8)
ARMS2f risk allele (rs10490924) 0.4c
−/− 7 (23.3) 16 (38.1)
+/− 17 (56.7) 18 (42.9)
+/+ 6 (20.0) 8 (19.0)
CFHg risk allele (rs1061170) 0.7c
−/− 5 (16.7) 5 (11.9)
+/− 17 (56.7) 28 (66.7)
+/+ 8 (26.7) 9 (21.4)
aAge-related macular degeneration.
b
Reticular pseudodrusen.
Am J Ophthalmol. Author manuscript; available in PMC 2015 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Boddu et al. Page 14
c
P-value from Fisher's exact test.
d
Kruskal-Wallis P-value.
e
P-value from Mantel's test for trend.31
fAge-related maculopathy susceptibility 2 gene; ARMS2 genotyping for one individual with large soft drusen was indeterminate and is not shown in
this data.
gComplement factor H gene; CFH genotyping for one individual with large soft drusen was indeterminate and is not shown in this data.
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Table 2
Prevalence of reticular pseudodrusen, odds ratios, 95% confidence intervals, and P-values among patients with
age-related macular degeneration presenting with different levels of risk factors at enrollment.
Risk factor Number of subjects RPD,a n (%) ORb (95% CIc) P-valued
Gender 0.003
Male 27 5 (18.5) 1
Female 46 25 (54.4) 5.2 (1.7-16)
Categorical age (years) 0.007e
≤ 80 25 6 (24.0) 1
81-86 20 7 (35.0) 1.7 (0.46-6.2)
≥ 87 28 17 (60.7) 4.9 (1.5-16)
Categorical age at AMDf onset (years) 0.0003e
≤ 70 25 3 (12.0) 1
71-82 24 12 (50.0) 7.3 (1.7-31.2)
≥ 83 24 15 (62.5) 12 (2.8-53)
Family member with AMDg 0.3
No 53 19 (36.9) 1
Yes 19 10 (52.6) 2.0 (0.69-5.7)
Smoking (> 6 months) 0.6
No 30 11 (36.7) 1
Yes 43 19 (44.2) 1.4 (0.53-3.6)
Hypertension 0.08
No 26 7 (26.9) 1
Yes 47 23 (48.9) 2.6 (0.92-7.3)
Hyperlipidemia 0.5
No 35 16 (45.7) 1
Yes 38 14 (36.8) 0.69 (0.27-1.8)
Diabetes mellitus 0.2
No 66 29 (43.9) 1
Yes 7 1 (14.3) 0.21 (0.02-1.9)
ARMS2h risk allele (rs10490924) 0.5
−/− 23 7 (30.4) 1
+/− 35 17 (48.6) 2.2 (0.71-6.5)
+/+ 14 6 (42.9) 1.7 (0.43-6.8)
CFHi risk allele (rs1061170) 0.6
−/− 10 5 (50.0) 1
+/− 45 17 (37.8) 0.61 (0.15-2.4)
+/+ 17 8 (47.1) 0.89 (0.19-4.2)
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a
Reticular pseudodrusen.
bOdds ratio.
cConfidence interval.
d
P-values are from Fisher's exact test unless otherwise noted.
e
P-value from Mantel's test for trend.
fAge-related macular degeneration.
gOne individual with reticular pseudodrusen could not provide data on family history of AMD.
hAge-related maculopathy susceptibility 2 gene; ARMS2 genotyping for one individual with large soft drusen was indeterminate and is not shown
in this data.
iComplement factor H gene; CFH genotyping for one individual with large soft drusen was indeterminate and is not shown in this data.
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Table 3
Exact multiple logistic regression model of risk factors for reticular pseudodrusen among patients with age-
related macular degeneration.
Risk factor ORa (95% CIb) P-value
Age at AMDc onset (years) 0.001
≤ 70 1
71-82 7.7 (2.3-55)
≥ 83 12 (2.3-85)
Gender 0.009
Male 1
Female 5.3 (1.4-23)
aOdds ratio.
bConfidence interval.
cAge-related macular degeneration.
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